

made to correct inadvertent typographical errors. No new matter has been added by these amendments.

Consideration of the elected and amended claims is now requested.

Respectfully submitted,

Ajay Bhatia et al.

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.
Reg. No. 44,614

Enclosure:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
(206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\JUDYD\355673_1.DOC

Version With Markings To Show Changes Made

In the Specification:

The paragraph on page 15, at lines 30-31 has been rewritten as follows:

SEQ ID NO:139 sets forth the amino acid sequence of serovar E protein ~~CT875~~
CT622.

The paragraph on page 16, at lines 1-2, has been rewritten as follows:

SEQ ID NO:140 sets forth the amino acid sequence of serovar E protein ~~CT622~~
CT875.

The paragraph on page 101, lines 15-26 has been rewritten as follows:

Two full-length recombinant proteins, CT622 and CT875, were expressed in *E. coli*. Both of these genes were identified using CtLGVII expression screening, but the serovar E homologues were expressed. The primers used to amplify these genes were based on serovar D sequences. The genes were amplified using serovar E genomic DNA as the template. Once amplified, the fragments were cloned in pET-17b with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clones fully sequenced. The DNA was then transformed into the expression host BL21-pLysS cells (Novagen) for production of the recombinant proteins. The proteins were induced with IPTG and purified on Ni-NTA agarose using standard methods. The DNA sequences for CTE622 and CTE875 are disclosed in SEQ ID NO:28 and 27 respectively, and their amino acid sequences are disclosed in SEQ ID NO: ~~140~~ 139 and ~~139~~ 140 respectively.

The paragraph bridging pages 101-102 has been rewritten as follows:

Five additional *Chlamydia trachomatis* genes were cloned. The *Chlamydia trachomatis* specific protein CT694, the protein CT695, and the L1 ribosomal protein, the DNA sequences of which are disclosed in SEQ ID NO:119, 120 and 121 respectively. The protein sequences of these 6X-histidine recombinant proteins are disclosed in SEQ ID NO: 122 (CT694), 123

(CT695), and 124 (L1 ribosomal protein). The genes ~~CT875~~ CT622 and ~~CT622~~ CT875, from serovar E were also cloned using pET17b as 6X-His fusion proteins. These recombinant proteins were expressed and purified and their amino acid sequences disclosed in SEQ ID NO:139 and 140, respectively.

In the Claims:

The following claims have been added:

19. (New) A method for stimulating and/or expanding T cells specific for a Chlamydia protein, comprising contacting T cells with a composition comprising at least an immunogenic portion of a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO: 139;
- (b) a polypeptide sequence having at least 95% identity with the polypeptide sequence of SEQ ID NO: 139; and
- (c) a polypeptide sequence having at least 99% identity with the polypeptide sequence of SEQ ID NO: 139.

20. (New) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component consisting of a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO: 139;
- (b) a polypeptide sequence having at least 95% identity with the polypeptide sequence of SEQ ID NO: 139; and
- (c) a polypeptide sequence having at least 99% identity with the polypeptide sequence of SEQ ID NO: 139.

Claims 10 and 12 have been cancelled.